Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by inthnoon Mar 26, 2023 12:24pm
814 Views
Post# 35361258

keep the enthusiasm in check

keep the enthusiasm in check
Yes we have had a great trial with the panc. But did anyone ever compare it to cornerstone pharmaceticals which had better results in their phase 1 trial than onc and then failed in their phase 3 trial. They actually had 3 cr's in their 20 patient orginal study, were allowed fast track but not AA....As Much as we all want this to work we need to understand that there is no guarantee and as much as I would like to see this partnered I would really prefer a buyout so as to not have to take a chance with the followup trial that might not prove out. I said before that 2 billion is reasonable considering all the risks that are still associated with future trials and really wonder if onc has ever been offered something similar and turned it down hoping for more. Just being a realist as the result and company comparisons so far are very similar.
<< Previous
Bullboard Posts
Next >>